689TiP NRG Oncology’s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)
Authors:
- Z. ZumstegZZZ. Zumsteg
- T. KarrisonTKT. Karrison
- MichaelsonMIMichaelson
- P. TranPTP. Tran
- R. KudchadkerRKR. Kudchadker
- F. FengFFF. Feng
- 1 September 2020
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 31, S546